Clinical Trial: Phase 1, Randomized, Placebo-Controlled, Blinded Study in Healthy Adults Challenged with Enterotoxigenic Escherichia Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA

U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06896136) titled 'Phase 1, Randomized, Placebo-Controlled, Blinded Study in Healthy Adults Challenged with Enterotoxigenic Escherichia Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA' on March 19.

Brief Summary: This is a phase 1, randomized, placebo-controlled, blinded study in up to 36 healthy adults, aged 18-45 years, challenged with Enterotoxigenic Escherichia coli, evaluating the safety, tolerability and anti-diarrheal activity of VENBETA6890, an orally administered, human monoclonal IgA.

Study Start Date: Feb. 11

Study Type: INTERVENTIONAL

Condition: Diarrhea Infect...